Table I.
Clinicopathological features of patients with HER2-overexpressing breast cancer.
| No. | Age (yr) | Intrinsic subtype | pT | Ki-67(%) | LN | Metastasis | wt-HER2 (fold) | delta-HER2 (fold) | delta/wt(%) | pSRC |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 35 | LumB | 2 | 49.6 | − | 46.2 | 32.3 | 1.5 | 2 | |
| 2 | 38 | LumB | 3 | 19.0 | + | Br | 54.8 | 49.5 | 3.9 | 1 |
| 3 | 42 | HER2+ | 2 | 82.0 | + | Ms | 16.6 | 25.7 | 3.4 | 1 |
| 4 | 42 | LumB | 1 | 16.7 | − | Br, Li | 4.0 | 3.1 | 1.7 | 1 |
| 5 | 42 | LumB | 2 | 38.5 | + | Br | 1.1 | 1.1 | 2.1 | 0 |
| 6 | 42 | LumB | 1 | 69.3 | + | 23.3 | 46.4 | 3.4 | 0 | |
| 7 | 43 | HER2+ | 1 | 52.7 | + | 3.6 | 5.4 | 3.4 | 2 | |
| 8 | 43 | HER2+ | − | 87.5 | + | Li, Lg, Bn, LN | 41.5 | 50.9 | 2.1 | 3 |
| 9 | 43 | LumB | 1 | 42.1 | − | 10.2 | 8.7 | 1.9 | 3 | |
| 10 | 45 | HER2+ | 1 | 44.3 | + | Br | 7.5 | 21.0 | 6.2 | 1 |
| 11 | 46 | LumB | 2 | 55.5 | + | Br, Skin | 5.7 | 7.2 | 2.8 | 0 |
| 12 | 47 | LumB | 1 | 29.4 | + | 0.5 | 0.3 | 1.4 | 1 | |
| 13 | 48 | HER2+ | 1 | 44.9 | − | Br | 6.6 | 8.1 | 2.7 | 1 |
| 14 | 48 | LumB | 1 | 79.4 | − | 94.4 | 222.1 | 3.0 | 2 | |
| 15 | 49 | LumB | 2 | 44.5 | − | Br, Bn | 598.4 | 19.3 | 0.1 | 2 |
| 16 | 50 | LumB | 2 | 75.2 | − | 169.5 | 150.1 | 2.0 | 3 | |
| 17 | 50 | LumB | 4 | 43.7 | + | 25.4 | 15.7 | 1.5 | 2 | |
| 18 | 50 | LumB | 2 | 69.4 | − | 39.7 | 40.4 | 1.8 | 3 | |
| 19 | 51 | HER2+ | 2 | 74.8 | + | 113.4 | 83.6 | 1.3 | 3 | |
| 20 | 52 | LumB | 1 | 58.4 | − | 4.1 | 4.0 | 2.2 | 3 | |
| 21 | 53 | HER2+ | 1 | 78.2 | − | 24.9 | 20.6 | 1.9 | 3 | |
| 22 | 55 | HER2+ | 2 | 63.4 | − | 177.3 | 156.0 | 1.5 | 0 | |
| 23 | 56 | HER2+ | 4 | 69.7 | + | 432 | 499.7 | 2.6 | 2 | |
| 24 | 57 | HER2+ | 2 | 92.3 | + | 87.7 | 114.2 | 2.3 | 2 | |
| 25 | 57 | LumB | 1 | 67.3 | − | 0.8 | 0.6 | 1.6 | 2 | |
| 26 | 59 | HER2+ | 1 | 64.7 | + | 9.3 | 7.8 | 1.9 | 2 | |
| 27 | 60 | HER2+ | 1 | 68.5 | − | 70.0 | 56.1 | 1.4 | 3 | |
| 28 | 61 | HER2+ | 1 | 51.2 | − | 2.0 | 1.8 | 2.1 | 1 | |
| 29 | 64 | HER2+ | 2 | 68.2 | + | 6.7 | 3.8 | 1.3 | 1 | |
| 30 | 64 | HER2+ | 1 | 43.7 | + | 1.7 | 2.4 | 3.2 | 0 | |
| 31 | 64 | HER2+ | 1 | 31.8 | − | 100.8 | 177.3 | 3.0 | 1 | |
| 32 | 65 | LumB | 1 | 56.4 | − | 315.2 | 128.9 | 0.7 | 3 | |
| 33 | 68 | HER2+ | 1 | 88.0 | + | 15.1 | 20.2 | 2.3 | 1 | |
| 34 | 69 | HER2+ | 4 | 92.3 | + | LN | 30.6 | 32.9 | 2.4 | 3 |
| 35 | 72 | HER2+ | 2 | 72.0 | − | 4.1 | 3.9 | 1.7 | 0 | |
| 36 | 73 | LumB | 1 | 28.5 | + | 10.9 | 9.8 | 2.0 | 3 | |
| 37 | 73 | LumB | 1 | 52.7 | − | 11.8 | 6.7 | 1.0 | 3 | |
| 38 | 78 | LumB | 2 | 74.4 | + | 55.7 | 64.9 | 2.0 | 3 | |
| 39 | 81 | HER2+ | 2 | 34.6 | + | 3.9 | 3.6 | 2.1 | 3 | |
| 40 | 85 | LumB | 2 | 80.1 | − | 203.7 | 370.9 | 2.4 | 3 |
Bn, bone; Br, brain; HER2+, human epidermal growth factor receptor 2-positive; LumB, luminal B; Lg, lung; Li, liver; LN, lymph node; Ms, muscle; pSRC, phosphorylated-SRC; pT, primary tumor staging; wt, wild type; yr, years of the age.